Skip to main navigation
Global
Japan
USA
Healthcare Professionals
Patients & Care Partners
Partnerships
Contact
About
Back
Transforming the treatment of cancer and other serious diseases
About Genmab
Our Purpose
Our History
Executive Committee
Board of Directors
FEATURED
A history of accomplishments rooted in science
Antibody Science
Back
Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Antibody Science Overview
Research
Antibody Research and Development
Antibody Technology Platforms
Artificial Intelligence
Innovation
Pipeline
Our Medicines
FEATURED
Science that can transform lives
Our Impact
Back
Discover how Genmab makes a positive impact for patients, communities and employees
Our Impact
Patient Engagement
Our Responsibility
Sustainability
Diversity, Equity & Inclusion
FEATURED
Incorporating the patient perspective
Investors
Back
Corporate and financial resources for Genmab investors, potential shareholders and analysts
Investor Relations
Resources
Genmab at a glance
Events & Presentations
News
Download Library
Investor Portal
Financials
Financial Calendar
Financial Reports
Annual Report
SEC Filings
Consolidated Key Figures
Stock Information
Share Performance
Analyst Coverage
ADR Program
Governance
Corporate Governance
Board Committees & Charters
Annual General Meeting
Compensation
Articles of Association
FEATURED
Genmab at a Glance
News & Insights
Back
Find press releases, articles and access media from Genmab
Latest Updates
News
Stories
Media Library
FEATURED
Revolutionizing Healthcare: How Genmab is Leveraging A.I
Careers
Healthcare Professionals
Patients & Care Partners
Partnerships
Contact
Genmab regional sites
Japan
USA
Event Details
Publication of the Interim Report for the First Half 2025 (after 5:00 PM CEST)
Aug 7, 2025
You are now leaving Genmab.com to go to our collaborator’s website.
If you continue, we encourage you to read the website’s privacy and cookie policy.
Continue
Cancel